Medical cannabis producer MGC Pharmaceuticals has struck a deal with an Israeli therapeutics start-up to develop an intra-nasal treatment for epilepsy.
Perth-based MGC will combine its cannabis compounds with SipNose's nasal delivery device to treat central nervous system disorders, including severe epilepsy and Dravet syndrome.
"There is a wealth of evidence available to show that medical cannabis can be an effective solution in the treatment of epilepsy," MGC co-founder and managing director Nativ Segev said in a statement on Thursday.
Share
